New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the <a target=_blank href=https ...
New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of ...
This special series marks Microsoft’s 50th anniversary by looking at what’s next for a company that reshaped the technology landscape. From a newsstand in Harvard Square to a storefront in ...
Elraglusib is a Class-Leading GSK-3ß Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer Trials Orphan Drug Designation in Soft Tissue Sarcomas Expands Company's ...
芝加哥和德克萨斯州沃思堡 - 临床阶段生物制药公司Actuate Therapeutics, Inc. (NASDAQ: ACTU)宣布,美国食品和药物管理局(FDA)已授予其研究性药物elraglusib用于软组织肉瘤(STS)治疗的孤儿药资格认定(ODD)。这一认定是elraglusib的重要里程碑,该药物是一种新型的糖原合成酶激酶-3β(GSK-3β)抑制剂,GSK-3β是一种参与肿瘤生长和 ...
Fort Worth, Texas, clinical-stage biopharmaceutical company Actuate said elraglusib has shown a favorable safety profile and antitumor activity across several solid tumors, including melanoma, Ewing ...
Leading GSK-3β Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer TrialsOrphan Drug Designation in Soft Tissue Sarcomas Expands Company’s Potential to Address Cancers ...
I'm sure the discussion is going to be fascinating. I'm told that, Kevin, this is -- this maybe the first time ever at an investor conference, a Chief Technology Officer of the world's, I think still ...
Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Actuate Therapeutics is a biopharmaceutical company. It focuses on the ...
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, including pancreatic cancer and Ewing sarcoma.
If you’re looking to switch your business from an LLC to an S corporation, the first thing to understand is that an S corporation is not a separate entity. An S corporation is where you make an ...